Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

3.550 -0.100 (-2.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,918,182
Open 3.590
Bid (Size) 3.520 (500)
Ask (Size) 3.580 (200)
Prev. Close 3.650
Today's Range 3.530 - 3.665
52wk Range 3.560 - 8.590
Shares Outstanding 93,500,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
The Netflix star partners with Myriad Genetics to tell her BRCA1 story and why she wants everyone to know about hereditary cancer testing 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions
Myriad Genetics began 2026 with results that fell short of Wall Street’s expectations, as the company posted modest year-over-year sales growth but missed on... 
Via StockStory
Topics Earnings

Performance

YTD
-42.2%
-42.2%
1 Month
-30.9%
-30.9%
3 Month
-21.1%
-21.1%
6 Month
-46.7%
-46.7%
1 Year
-19.9%
-19.9%

More News

Read More
News headline image
3 of Wall Street’s Favorite Stocks with Open Questions
Via StockStory
Myriad Genetics (NASDAQ:MYGN) Plunges 14% After Q1 Earnings Beat Revenue Estimates But Miss EPS ↗
Via Chartmill
Topics Earnings
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure Margins
Via StockStory
News headline image
Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%
Via StockStory
News headline image
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
3 Small-Cap Stocks We Think Twice About
Via StockStory
News headline image
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Cash-Burning Stock to Target This Week and 2 We Question
Via StockStory
News headline image
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
3 Healthcare Stocks with Open Questions
Via StockStory
News headline image
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know
Via StockStory
Topics Government Stocks
News headline image
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off
Via StockStory
News headline image
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons to Sell MYGN and 1 Stock to Buy Instead
Via StockStory
News headline image
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know
Via StockStory
Topics Artificial Intelligence Earnings
News headline image
3 Stocks Under $10 We Keep Off Our Radar
Via StockStory

Frequently Asked Questions

Is Myriad Genetics, Inc. - Common Stock publicly traded?
Yes, Myriad Genetics, Inc. - Common Stock is publicly traded.
What exchange does Myriad Genetics, Inc. - Common Stock trade on?
Myriad Genetics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Myriad Genetics, Inc. - Common Stock?
The ticker symbol for Myriad Genetics, Inc. - Common Stock is MYGN on the Nasdaq Stock Market
What is the current price of Myriad Genetics, Inc. - Common Stock?
The current price of Myriad Genetics, Inc. - Common Stock is 3.550
When was Myriad Genetics, Inc. - Common Stock last traded?
The last trade of Myriad Genetics, Inc. - Common Stock was at 05/19/26 04:00 PM ET
What is the market capitalization of Myriad Genetics, Inc. - Common Stock?
The market capitalization of Myriad Genetics, Inc. - Common Stock is 331.93M
How many shares of Myriad Genetics, Inc. - Common Stock are outstanding?
Myriad Genetics, Inc. - Common Stock has 332M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.